Targeting of KRAS mutant tumors by HSP90 inhibitors involves degradation of STK33
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Previous efforts to develop drugs that directly inhibit the activity of mutant KRAS, the most commonly mutated human oncogene, have not been successful. Cancer cells driven by mutant KRAS require expression of the serine/threonine kinase STK33 for their viability and proliferation, identifying STK33 as a context-dependent therapeutic target. However, specific strategies for interfering with the critical functions of STK33 are not yet available. Here, using a mass spectrometry-based screen for STK33 protein interaction partners, we report that the HSP90/CDC37 chaperone complex binds to and stabilizes STK33 in human cancer cells. Pharmacologic inhibition of HSP90, using structurally divergent small molecules currently in clinical development, induced proteasome-mediated degradation of STK33 in human cancer cells of various tissue origin in vitro and in vivo, and triggered apoptosis preferentially in KRAS mutant cells in an STK33-dependent manner. Furthermore, HSP90 inhibitor treatment impaired sphere formation and viability of primary human colon tumor-initiating cells harboring mutant KRAS. These findings provide mechanistic insight into the activity of HSP90 inhibitors in KRAS mutant cancer cells, indicate that the enhanced requirement for STK33 can be exploited to target mutant KRAS-driven tumors, and identify STK33 depletion through HSP90 inhibition as a biomarker-guided therapeutic strategy with immediate translational potential.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Epidermal growth factor receptor mutations in lung cancer
Sharma, S. V., Bell, D. W., Settleman, J., & Haber, D. A. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2088 · Cited by 3,170 · cited 1×
“However, even though the identification of acquired genetic alterations that cause certain cancer types has led to remarkable therapeutic successes (Hudis, 2007; Sharma et al., 2007; Druker, 2009), many cancer-associated mutations are difficult to inhibit directly.”
BackgroundTargeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer
Roberts, P. J., & Der, C. J. (2007) · Oncogene · doi:10.1038/sj.onc.1210422 · Cited by 2,788
International network of cancer genome projects
The International Cancer Genome Consortium (2010) · Nature · doi:10.1038/nature08987 · Cited by 2,299
RAS oncogenes: the first 30 years
Malumbres, M., & Barbacid, M. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1097 · Cited by 1,902 · cited 2×
“Although oncogenic KRAS alleles were first identified >20 yr ago, mutant KRAS has evaded all attempts at therapeutic targeting so far (Malumbres and Barbacid, 2003; Downward, 2003; Roberts and Der, 2007).”
BackgroundHSP90 at the hub of protein homeostasis: emerging mechanistic insights
Taipale, M., Jarosz, D. F., & Lindquist, S. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2918 · Cited by 1,818
Ras oncogenes: split personalities
Karnoub, A. E., & Weinberg, R. A. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2438 · Cited by 1,467 · cited 1×
“However, STK33 degradation was accompanied by induction of apoptosis, as indicated by increased PARP cleavage, in mutant KRAS- and STK33-dependent cell in adenocarcinomas of the pancreas, lung, and colon (Karnoub and Weinberg, 2008).”
BackgroundA Genome-wide RNAi Screen Identifies Multiple Synthetic Lethal Interactions with the Ras Oncogene
Luo, J., Emanuele, M. J., Li, D., Creighton, C. J., Schlabach, M. R., Westbrook, T. F., Wong, K.-K., & Elledge, S. J. (2009) · Cell · doi:10.1016/j.cell.2009.05.006 · Cited by 1,017
PI3K Pathway Activation Mediates Resistance to MEK Inhibitors in KRAS Mutant Cancers
Wee, S., Jagani, Z., Xiang, K. X., Loo, A., Dorsch, M., Yao, Y.-M., Sellers, W. R., Lengauer, C., & Stegmeier, F. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4765 · Cited by 455
Puyol, M., Martín, A., Dubus, P., Mulero, F., Pizcueta, P., Khan, G., Guerra, C., Santamaría, D., & Barbacid, M. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.05.025 · Cited by 415
Update on Hsp90 Inhibitors in Clinical Trial
Kim, Y., Alarcon, S., Lee, S., Lee, M.-J., Giaccone, G., Neckers, L., & Trepel, J. (2009) · Current Topics in Medicinal Chemistry · doi:10.2174/156802609789895728 · Cited by 311
Cited by
HSP90AB1: Helping the good and the bad
Haase, M., & Fitze, G. (2016) · Gene · doi:10.1016/j.gene.2015.08.063 · Cited by 179
Synthetic Lethal Vulnerabilities in KRAS-Mutant Cancers
Aguirre, A. J., & Hahn, W. C. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a031518 · Cited by 90
“…have been developed and these molecules have conclusively demonstrated that STK33 kinase activity is not required for KRAS-mutant cancers (Babij et al. 2011; Luo et al. 2012), although other strategies that result in loss of STK33 protein may still hold therapeutic potential (Azoitei et al. 2012).”
BackgroundPerkhofer, L., Walter, K., Costa, I. G., Carrasco, M. C. R., Eiseler, T., Hafner, S., Genze, F., Zenke, M., Bergmann, W., Illing, A., et al. (2016) · Stem Cell Research · doi:10.1016/j.scr.2016.08.007 · Cited by 39
“To investigate pro-tumourigenic effects of TBX3 we performed xenotransplantation experiments using a chicken chorioallantoic membrane (CAM) assay that faithfully mimics in vivo tumour growth (Muller et al., 2015; Azoitei et al., 2014; Azoitei et al., 2012; Azoitei et al., 2010).”
MethodSelf-citation
Metadata
- Authors
- Azoitei, N., Hoffmann, C. M., Ellegast, J. M., Ball, C. R., Obermayer, K., Gößele, U., Koch, B., Faber, K., Genze, F., Schrader, M., Kestler, H. A., Döhner, H., Chiosis, G., Glimm, H., Fröhling, S., & Scholl, C.
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2012-03-26
- Volume
- 209
- Issue
- 4
- Pages
- 697-711
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- OpenAlex
- W2160823559
- Cited by
- 74
- References
- 11
- FWCI
- 2.21
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeting of KRAS mutant tumors by HSP90 inhibitors involves degradation of STK33. https://app.cochat.ai/papers/10.1084/jem.20111910
- The paper
- Azoitei, N., Hoffmann, C. M., Ellegast, J. M., Ball, C. R., Obermayer, K., Gößele, U., Koch, B., Faber, K., Genze, F., Schrader, M., Kestler, H. A., Döhner, H., Chiosis, G., Glimm, H., Fröhling, S., & Scholl, C. (2012). Targeting of KRAS mutant tumors by HSP90 inhibitors involves degradation of STK33. Journal of Experimental Medicine. https://doi.org/10.1084/jem.20111910
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.